Arjen Joosse
Rotterdam, ZH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
Neutralizing the IL-12/IL-23 p40 subunit prevents immune checkpoint blockade toxicity without compromising antitumor efficacy.
Journal: Cancer immunology research
Published: February 09, 2026
Thromboembolism in patients with melanoma receiving immune checkpoint inhibitors: incidence and risk factors.
Journal: Immuno-oncology technology
Published: July 21, 2025
Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma.
Journal: Clinical pharmacology and therapeutics
Published: July 04, 2025
Onset and progression of atherosclerosis in patients with melanoma treated with immune checkpoint inhibitors.
Journal: Journal for immunotherapy of cancer
Published: April 14, 2025
Size matters: Early progression of melanoma brain metastases after treatment with immune checkpoint inhibitors.
Journal: Neuro-oncology advances
Published: March 07, 2025
From ICI to ICU: A systematic review of patients with solid tumors who are treated with immune checkpoint inhibitors (ICI) and admitted to the intensive care unit (ICU).
Journal: Cancer treatment reviews
Published: February 18, 2025
Bioequivalence of alternative pembrolizumab dosing regimens: current practice and future perspectives.
Journal: Cancer communications (London, England)
Published: September 25, 2024
From decision to reflection: understanding the experiences and unmet care needs of patients treated with immunotherapy for melanoma in the adjuvant or metastatic setting.
Journal: BMC cancer
Published: April 24, 2024
The development of brain metastases in patients with different therapeutic strategies for metastatic renal cell cancer.
Journal: International journal of cancer
Published: January 09, 2024
Impact of Novel Treatments in Patients with Melanoma Brain Metastasis: Real-World Data.
Journal: Cancers
Published: February 01, 2023
Last Updated: 09/26/2026